Chemotherapy and radiation given together could help elderly patients with lung cancer live longer

May 21, 2012, Lancet

Despite more than two-thirds of lung cancer cases being diagnosed in people 65 years or older, there have been few trials of treatments in this age group, and it is not known if the standard treatment for patients with inoperable non-small-cell lung cancer (NSCLC)—combined chemoradiotherapy—is suitable for elderly patients. However, new research published Online First in The Lancet Oncology shows that giving a daily low-dose of the chemotherapy drug carboplatin at the same time as radiotherapy significantly prolongs survival in elderly patients compared with radiotherapy alone.

"[Until now] evidence supporting standard treatment with concurrent chemoradiotherapy was from clinical trials in which elderly, especially frail elderly patients, were under-represented"*, explains Shinji Atagi from Kinki-chuo Chest Medical Center, Osaka, Japan who led the research. "This trial is the first to show that combined radiotherapy can safely improve outcome of stage III NSCLC in elderly patients."

The Japan Clinical Oncology Group 0301 trial randomly assigned 200 patients aged 71 years or older with inoperable NSCLC to chemoradiotherapy (with carboplatin that is known to have a more favourable toxicity profile in elderly patients) or radiotherapy alone.

Results showed that patients given combined chemoradiotherapy were nearly a third less likely to die than those given alone at a median follow-up of 19.4 months (overall survival 22.4 vs 16.9 months).

Although chemoradiation was well tolerated more than half of patients experienced grade 3-4 toxic effects including leucopenia and neutropenia, compared with none in the radiotherapy-alone group. Infections were also more common with chemoradiotherapy, but most were manageable with treatment.

The authors conclude: "Combined treatment is feasible and tolerable in elderly patients with locally advanced NSCLC and should be considered for this population."

In an linked Comment, Juan Wisnivesky from Mount Sinai School of Medicine, New York and Gary Strauss from Tufts Medical Center, Boston caution: "The unexpectedly large survival advantage for concurrent chemoradiation raises concerns about the representativeness of the sample of elderly patients…and the results might not be valid for the broader population of older patients with stage III NSCLC…Additional validation of the present findings is needed before concurrent chemoradiation can be considered standard of care in ."

Explore further: Elderly Dutch lung patients' survival improved by new treatment options between 2003-2009

More information: Study online: www.thelancet.com/journals/lan … (12)70139-0/abstract

Related Stories

Elderly Dutch lung patients' survival improved by new treatment options between 2003-2009

July 6, 2011
New developments such as stereotactic ablative radiotherapy and improvements in surgical care in early-stage lung cancer have led to large survival gains for elderly Dutch patients, according to a population-based study presented ...

Concurrent chemo and radiation confers survival benefit in nasopharyngeal carcinoma patients

November 5, 2011
The combination of chemotherapy and radiation significantly improved the 5-year overall survival of patients with stage II nasopharyngeal carcinoma (NPC), according to a phase III study published Nov. 4 in the Journal of ...

Recommended for you

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

Presurgical targeted therapy delays relapse of high-risk stage 3 melanoma

January 17, 2018
A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared to standard-of-care surgery for patients with stage 3 disease, researchers at ...

Dulling cancer therapy's double-edged sword

January 17, 2018
Researchers have discovered that killing cancer cells can actually have the unintended effect of fueling the proliferation of residual, living cancer cells, ultimately leading to aggressive tumor progression.

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

January 16, 2018
WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children's National Health System clinician-researchers ...

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.